MedTrace Logo

PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant

NCT01841333 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-01-25

Study results available
· View outcomes & findings →

Summary

This phase II trial will test whether the Hedgehog signaling pathway inhibitor PF-04449913 can decrease disease relapse in high-risk patients with acute myeloid leukemia after donor stem cell transplant.

Conditions

  • Adult Acute Myeloid Leukemia in Remission
  • Recurrent Adult Acute Myeloid Leukemia

Interventions

DRUG

PF-04449913

100mg given orally

Sponsors & Collaborators

  • The Leukemia and Lymphoma Society

    collaborator OTHER

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Daniel A Pollyea, MD, MS · University of Colorado, Denver

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-29
Primary Completion
2019-05-08
Completion
2020-02-04

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01841333 on ClinicalTrials.gov